Pediatric AIDS: Maternal-Fetal and Maternal-Infant Transmission of Lentiviruses and Effects on Infant Development in Nonhuman Primates

Primate Models of Children's Health and Developmental Disabilities

Volumn , Issue , 2008, Pages 259-282

  Van Rompay, Koen K A ^a   Haigwood, Nancy L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882466434     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012373743-4.50012-6     Document Type: Chapter

References (135)

1. Abel K., Pahar B., Van Rompay K.K., et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 2006, 80:6357-6367.
2. Adamson D.C., Dawson T.M., Zink M.C., Clements J.E., Dawson V.L. Neurovirulent simian immunodeficiency virus infection induces neuronal, endothelial, and glial apoptosis. Mol Med 1996, 2:417-428.
3. Amedee A.M., Lacour N., Gierman J.L., et al. Genotypic selection of simian immunodeficiency virus in macaque infants infected transplacentally. J Virol 1995, 69:7982-7990.
4. Amedee A.M., Rychert J., Lacour N., Fresh L., Ratterree M. Viral and immunologicalfactors associated with breast milk transmission of SIV in rhesus macaques. Retrovirology 2004, 1:17.
5. Baba T.W., Koch J., Mittler E.S., et al. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses 1994, 10:351-357.
6. Baba T.W., Liska V., Khimani A.H., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999, 5:194-203.
7. Bamji M., Thea D.M., Weedon J., et al. Prospective study of human immunodeficiency virus 1-related disease among 512 infants born to infected women in New York City. The New York City Perinatal HIV Transmission Collaborative Study Group. Pediatr Infect Dis J 1996, 15:891-898.
8. Barin F., Jourdain G., Brunet S., et al. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J Infect Dis 2006, 193:1504-1511.
9. Betts M.R., Price D.A., Brenchley J.M., et al. The functional profile of primary human antiviral CD8 T cell effector activity is dictated by cognate peptide concentration. J Immunol 2004, 172:6407-6417.
10. Blanchette N., Smith M.L., Fernandes-Penney A., King S., Read S. Cognitive and motor development in children with vertically transmitted HIV infection. Brain Cogn 2001, 46:50-53.
11. Blanchette N., Smith M.L., King S., Fernandes-Penney A., Read S. Cognitive development in school-age children with vertically transmitted HIV infection. Dev Neuropsychol 2002, 21:223-241.
12. Bontrop R.E., Watkins D.I. MHC polymorphism: AIDS susceptibility in non-human primates. Trends Immunol 2005, 26:227-233.
13. Brenchley J.M., Schacker T.W., Ruff L.E., et al. CD4 T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
14. Bryson Y.J., Pang S., Wei L.S., Dickover R., Diagne A., Chen I.S. Clearance of HIV infection in a perinatally infected infant. N Engl J Med 1995, 332:833-838.
15. Chase C., Ware J., Hittelman J., et al. Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group. Pediatrics 2000, 106:E25.
16. Chersich M.F., Gray G.E. Progress and emerging challenges in preventing mother-to-child transmission. Curr Infect Dis Rep 2005, 7:393-400.
17. Chersich M.F., Urban M.F., Venter F.W., et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006, 3:11.
18. Chohan B., Lavreys L., Rainwater S.M., Overbaugh J. Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol 2005, 79:10701-10708.
19. Chun T.W., Davey R.T., Engel D., Lane H.C., Fauci A.S. Re-emergence of HIV after stopping therapy. Nature 1999, 401:874-875.
20. Chung M.H., Kiarie J.N., Richardson B.A., Lehman D.A., Overbaugh J., John-Stewart G.C. Breast milk HIV-1 suppression and decreased transmission: a randomized trial compar-ing HIVNET 012 nevirapine versus short-course zidovudine. AIDS 2005, 19:1415-1422.
21. Clements J.E., Anderson M.G., Zink M.C., Joag S.V., Narayan O. The SIV model of AIDS encephalopathy. Role of neurotropic viruses in diseases. Res Publ Assoc Res Nerv Ment Dis 1994, 72:147-157.
22. Clements J.E., Babas T., Mankowski J.L., et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis 2002, 186:905-913.
23. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
24. Dickover R.E., Garratty E.M., Plaeger S., Bryson Y.J. Perinatal transmission of major, minor, and multiple maternal human immunodefiiency virus type 1 variants in utero and intra-partum. J Virol 2001, 75:2194-2203.
25. Dickover R., Garratty E., Yusim K., Miller C., Korber B., Bryson Y. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol 2006, 80:6525-6533.
26. Eshleman S.H., Hoover D.R., Chen S., et al. Resistance after single-dose nevirapine prophy-laxis emerges in a high proportion of Malawian newborns. AIDS 2005, 19:2167-2169.
27. Fang G., Burger H., Grimson R., et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995, 92:12100-12104.
28. Fang G., Weiser B., Kuiken C., et al. Recombination following superinfection by HIV-1. AIDS 2004, 18:153-159.
29. Fazely F., Sharma P.L., Fratazzi C., et al. Simian immunodeficiency virus infection via amniotic fluid: a model to study fetal immunopathogenesis and prophylaxis. J Acquir Immune Defic Syndr 1993, 6:107-114.
30. Ferrantelli F., Hofmann-Lehmann R., Rasmussen R.A., et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003, 17:301-309.
31. Ferrantelli F., Rasmussen R.A., Buckley K.A., et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004, 189:2167-2173.
32. Fox H.S., Weed M.R., Huitron-Resendiz S., et al. Antiviral treatment normalizes neurophysiological but not movement abnormalities in simian immunodeficiency virus-infected monkeys. J Clin Invest 2000, 106:37-45.
33. Gaillard P., Fowler M.G., Dabis F., et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breast-feeding: from animal studies to randomized clinical trials. J Acquir Immune Defic Syndr 2004, 35:178-187.
34. Gardner M.B. The importance of nonhuman primate research in the battle against AIDS: a historical perspective. J Med Primatol 1993, 22:86-91.
35. George M.D., Reay E., Sankaran S., Dandekar S. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4 T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 2005, 79:2709-2719.
36. Gray R.A., Wilcox K.M., Zink M.C., Weed M.R. Impaired performance on the object retrieval-detour test of executive function in the SIV/macaque model of AIDS. AIDS Res Hum Retroviruses 2006, 22:1031-1035.
37. Grob P.M., Cao Y., Muchmore E., et al. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat Med 1997, 3:665-670.
38. Guadalupe M., Reay E., Sankaran S., et al. Severe CD4 T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003, 77:11708-11717.
39. Guay L.A., Musoke P., Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354:795-802.
40. Hahn B.H., Shaw G.M., De Cock K.M., Sharp P.M. AIDS as a zoonosis: scientific and public health implications. Science 2000, 287:607-614.
41. Haigwood N.L. Progress and challenges in therapies for AIDS in nonhuman primate models. J Med Primatol 1999, 28:154-163.
42. Haigwood N.L. Predictive value of primate models for AIDS. AIDS Rev 2004, 6:187-198.
43. Haigwood N.L., Montefiori D.C., Sutton W.F., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004, 78:5983-5995.
44. Hayami M., Igarashi T., Kuwata T., et al. Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use. Leukemia 1999, 13(suppl 1):S42-S47.
45. Heise C., Miller C.J., Lackner A., Dandekar S. Primary acute simian immunodeficiency virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction. J Infect Dis 1994, 169:1116-1120.
46. Hel Z., Venzon D., Poudyal M., et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 2000, 6:1140-1146.
47. Hirsch V.M., Dapolito G., Hahn A., et al. Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia. J Virol 1998, 72:6482-6489.
48. Ho R.J., Agy M.B., Morton W.R., et al. Development of a chronically catheterized maternal-fetal macaque model to study in utero mother-to-fetus HIV transmission: a preliminary report. J Med Primatol 1996, 25:218-224.
49. Ho R.J., Larsen K., Kinman L., et al. Characterization of a maternal-fetal HIV transmission model using pregnant macaques infected with HIV-2(287). J Med Primatol 2001, 30:131-140.
50. Hu S.L. Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord 2005, 5:193-201.
51. Hurtrel B., Chakrabarti L., Hurtrel M., Maire M.A., Dormont D., Montagnier L. Early SIV encephalopathy. J Med Primatol 1991, 20:159-166.
52. Hurtrel B., Chakrabarti L., Hurtrel M., Montagnier L. Target cells during early SIV encephalopathy. Res Virol 1993, 144:41-46.
53. Jaspan H.B., Robinson J.E., Amedee A.M., Van Dyke R.B., Garry R.F. Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies. J Clin Virol 2004, 31:190-197.
54. Jayaraman P., Mohan D., Polacino P., et al. Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina. J Med Primatol 2004, 33:243-250.
55. Jayaraman P., Haigwood N.L. Animal models for perinatal transmission of HIV-1. Front Biosci 2006, 11:2828-2844.
56. Jayaraman P., Zhu T., Misher L., et al. Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J Virol 2007, 81:822-834.
57. Jin X., Roberts C.G., Nixon D.F., et al. Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators. J Infect Dis 1998, 178:1317-1326.
58. Joag S.V., Adams R.J., Pinson D.M., Adany I., Narayan O. Intracerebral infusion of TNF-alpha and IL-6 failed to activate latent SIV infection in the brains of macaques inoculated with macrophage-tropic neuroadapted SIVmac. J Leukoc Biol 1994, 56:353-357.
59. Kemal K.S., Foley B., Burger H., et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci USA 2003, 100:12972-12977.
60. Kemal K.S., Burger H., Mayers D., et al. HIV-1 drug resistance in variants from the female genital tract and plasma. J Infect Dis 2007, 195:535-545.
61. Kinman L.M., Worlein J.M., Leigh J., et al. HIV in central nervous system and behavioral development: an HIV-2287 macaque model of AIDS. AIDS 2004, 18:1363-1370.
62. Lackner A.A., Dandekar S., Gardner M.B. Neurobiology of simian and feline immunodeficiency virus infections. Brain Pathol 1991, 1:201-212.
63. Lisziewicz J., Trocio J., Xu J., et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005, 19:35-43.
64. Lobato M.N., Caldwell M.B., Ng P., Oxtoby M.J. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium. J Pediatr 1995, 126:710-715.
65. Lockman S., Shapiro R.L., Smeaton L.M., et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007, 356:135-147.
66. Lohman B.L., Slyker J., Mbori-Ngacha D., et al. Prevalence and magnitude of human immunodeficiency virus (HIV) type 1-specific lymphocyte responses in breast milk from HIV-1-seropositive women. J Infect Dis 2003, 188:1666-1674.
67. Lori F., Lewis M.G., Xu J., et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000, 290:1591-1593.
68. Luzuriaga K., Sullivan J.L. Viral and immunopathogenesis of vertical HIV-1 infection. Pediatr Clin North Am 2000, 47:65-78.
69. Luzuriaga K., Sullivan J.L. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev 2002, 4:21-26.
70. Mankowski J.L., Queen S.E., Kirstein L.M., et al. Alterations in blood-brain barrier glucose transport in SIV-infected macaques. J Neurovirol 1999, 5:695-702.
71. Marcario J.K., Manaye K.F., SantaCruz K.S., Mouton P.R., Berman N.E., Cheney P.D. Severe subcortical degeneration in macaques infected with neurovirulent simian immunodeficiency virus. J Neurovirol 2004, 10:387-399.
72. Marthas M.L., Banapour B., Sutjipto S., et al. Rhesus macaques inoculated with molecularly cloned simian immunodeficiency virus. J Med Primatol 1989, 18:311-319.
73. Marthas M.L., van Rompay K.K., Otsyula M., et al. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 1995, 69:4198-4205.
74. Martin Amedee A., Lacour N., Martin L.N., et al. Genotypic analysis of infant macaques infected transplacentally and orally. J Med Primatol 1996, 25:225-235.
75. Martin S.C., Wolters P.L., Toledo-Tamula M.A., Zeichner S.L., Hazra R., Civitello L. Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Dev Neuropsychol 2006, 30:633-657.
76. Mbori-Ngacha D., Richardson B.A., Overbaugh J., et al. Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments. J Virol 2003, 77:7702-7705.
77. McCormick-Davis C., Dalton S.B., Hout D.R., et al. A molecular clone of simian-human immunodeficiency virus (DeltavpuSHIV(KU-1bMC33)) with a truncated, non-membrane-bound vpu results in rapid CD4(+) T cell loss and neuro-AIDS in pig-tailed macaques. Virology 2000, 272:112-126.
78. Milush J.M., Kosub D., Marthas M., et al. Rapid dissemination of SIV following oral inoculation. AIDS 2004, 18:2371-2380.
79. Miyake A., Enose Y., Ohkura S., et al. The quantity and diversity of infectious viruses in various tissues of SHIV-infected monkeys at the early and AIDS stages. Arch Virol 2004, 149:943-955.
80. Muro E., Droste J.A., Hofstede H.T., Bosch M., Dolmans W., Burger D.M. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr 2005, 39:419-421.
81. Musoke P., Guay L.A., Bagenda D., et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999, 13:479-486.
82. Nag P., Kim J., Sapiega V., et al. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 2004, 190:1970-1978.
83. Nduati R. Breastfeeding and HIV-1 infection. A review of current literature. Adv Exp Med Biol 2000, 478:201-210.
84. Nduati R., John G., Mbori-Ngacha D., et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000, 283:1167-1174.
85. Newell M.L. Vertical transmission of HIV-1 infection. Trans R Soc Trop Med Hyg 2000, 94:1-2.
86. Nowak P., Karlsson A.C., Naver L., Bohlin A.B., Piasek A., Sonnerborg A. The selection and evolution of viral quasispecies in HIV-1 infected children. HIV Med 2002, 3:1-11.
87. Otsyula M.G., Miller C.J., Tarantal A.F., et al. Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251. Virology 1996, 222:275-278.
88. Rausch D.M., Heyes M., Eiden L.E. Effects of chronic zidovudine administration on CNS function and virus burden after perinatal SIV infection in rhesus monkeys. Adv Neuroimmunol 1994, 4:233-237.
89. Rausch D.M., Heyes M.P., Murray E.A., Eiden L.E. Zidovudine treatment prolongs survival and decreases virus load in the central nervous system of rhesus macaques infected perinatally with simian immunodeficiency virus. J Infect Dis 1995, 172:59-69.
90. Regoes R.R., Longini I.M., Feinberg M.B., Staprans S.I. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med 2005, 2:e249.
91. Rich K.C., Fowler M.G., Mofenson L.M., et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Pediatrics 2000, 105:e8. Women and Infants Transmission Study Group.
92. Rousseau C.M., Nduati R.W., Richardson B.A., et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 2004, 190:1880-1888.
93. Ruprecht R.M., Fratazzi C., Sharma P.L., Greene M.F., Penninck D., Wyand M. Animal models for perinatal transmission of pathogenic viruses. Ann N Y Acad Sci 1993, 693:213-228.
94. Ruprecht R.M., Baba T.W., Liska V., et al. Oral SIV, SHIV, and HIV type 1 infection. AIDS Res Hum Retroviruses 1998, 14(suppl 1):S97-S103.
95. Ruprecht R.M., Baba T.W., Liska V., et al. Oral transmission of primate lentiviruses. J Infect Dis 1999, 179(suppl 3):S408-S412.
96. Rychert J., Lacour N., Amedee A.M. Genetic analysis of simian immunodeficiency virus expressed in milk and selectively transmitted through breastfeeding. J Virol 2006, 80:3721-3731.
97. Safrit J.T., Ruprecht R., Ferrantelli F., et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2004, 35:169-177.
98. Scarlatti G. Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries. AIDS Rev 2004, 6:67-78.
99. Sestak K. Chronic diarrhea and AIDS: insights into studies with non-human primates. Curr HIV Res 2005, 3:199-205.
100. Shen A., Zink M.C., Mankowski J.L., et al. Resting CD4 T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003, 77:4938-4949.
101. Shen A., Yang H.C., Zhou Y., et al. Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol 2007, 81:1660-1670.
102. Smith M.S., Niu Y., Buch S., et al. Active simian immunodeficiency virus (strain smmPGm) infection in macaque central nervous system correlates with neurologic disease. J Acquir Immune Defic Syndr 2005, 38:518-530.
103. St John A.M., Kumar A., Cave C. Reduction in perinatal transmission and mortality from human immunodeficiency virus after intervention with zidovudine in Barbados. Pediatr Infect Dis J 2003, 22:422-426.
104. Staprans S.I., Feinberg M.B. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines 2004, 3(suppl):S5-S32.
105. Tarantal A.F., Marthas M.L., McChesney M.D., et al. Effects of SIV infection on fetal development and prenancy outcome in the rhesus macaque (Macaca mulatta). Pediatr AIDS HIV Infect Fetus Adolesc 1993, 4:373-380.
106. Tarantal A.F., Marthas M.L., Gargosky S.E., et al. Effects of viral virulence on intrauterine growth in SIV-infected fetal rhesus macaques (Macaca mulatta). J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:129-138.
107. Tarantal A.F., Castillo A., Ekert J.E., Bischofberger N., Martin R.B. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002, 29:207-220.
108. Tarantal A.F., Marthas M.L., Shaw J.P., Cundy K., Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:323-333.
109. Trichel A.M., Roberts E.D., Wilson L.A., Martin L.N., Ruprecht R.M., Murphey-Corb M. SIV/DeltaB670 transmission across oral, colonic, and vaginal mucosae in the macaque. J Med Primatol 1997, 26:3-10.
110. Van Rompay K.K. Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments. AIDS Rev 2005, 7:67-83.
111. Van Rompay K.K., Marthas M.L., Ramos R.A., et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3 azido-3 -deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992, 36:2381-2386.
112. Van Rompay K.K.A., Otsyula M.G., Marthas M.L., et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995, 39:125-131.
113. Van Rompay K.K.A., Cherrington J.M., Marthas M.L., et al. 9-[2-(Phosphono-methoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 1996, 40:2586-2591.
114. Van Rompay K.K.A., Berardi C.J., Dillard-Telm S., et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998, 177:1247-1259.
115. Van Rompay K.K., Greenier J.L., Cole K.S., et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol 2003, 77:179-190.
116. Van Rompay K.K., Brignolo L.L., Meyer D.J., et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004, 48:1469-1487.
117. Van Rompay K.K., Singh R.P., Brignolo L.L., et al. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. J Acquir Immune Defic Syndr 2004, 36:900-914.
118. Van Rompay K.K., Abel K., Lawson J.R., et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005, 38:124-134.
119. Van Rompay K.K., Singh R.P., Heneine W., et al. Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol 2006, 80:6399-6410.
120. Van Rompay K.K.A., Kearney B.P., Sexton J.J., et al. Evaluation of oral tenofovir disoproxyl fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 2006, 43:6-14.
121. Veazey R.S., Lackner A.A. HIV swiftly guts the immune system. Nat Med 2005, 11:469-470.
122. Veazey R.S., DeMaria M., Chalifoux L.V., et al. Gastrointestinal tract as a major site of CD4 T-cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
123. Veazey R.S., Lifson J.D., Pandrea I., Purcell J., Piatak M., Lackner A.A. Simian immunodeficiency virus infection in neonatal macaques. J Virol 2003, 77:8783-8792.
124. Watson A., McClure J., Ranchalis J., et al. Early postinfection antiviral treatment reduces viral load and prevents CD4 cell decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses 1997, 13:1375-1381.
125. Weed M.R., Steward D.J. Neuropsychopathology in the SIV/macaque model of AIDS. Front Biosci 2005, 10:710-727.
126. Weed M.R., Hienz R.D., Brady J.V., et al. Central nervous system correlates of behavioral deficits following simian immunodeficiency virus infection. J Neurovirol 2003, 9:452-464.
127. Weed M.R., Gold L.H., Polis I., Koob G.F., Fox H.S., Taffe M.A. Impaired performance on a rhesus monkey neuropsychological testing battery following simian immunodeficiency virus infection. AIDS Res Hum Retroviruses 2004, 20:77-89.
128. Wilfert C.M., Fowler M.G. Balancing maternal and infant benefits and the consequences of breast-feeding in the developing world during the era of HIV infection. J Infect Dis 2007, 195:165-167.
129. Worlein J.M., Leigh J., Larsen K., et al. Cognitive and motor deficits associated with HIV-2(287) infection in infant pigtailed macaques: a nonhuman primate model of pediatric neuro-AIDS. J Neurovirol 2005, 11:34-45.
130. Wu X., Parast A.B., Richardson B.A., et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006, 80:835-844.
131. Zhu T., Corey L., Hwangbo Y., et al. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003, 77:6108-6116.
132. Zink M.C., Clements J.E. A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease. J Neurovirol 2002, 8(suppl 2):42-48.
133. Zink M.C., Suryanarayana K., Mankowski J.L., et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 1999, 73:10480-10488.
134. Zink M.C., Uhrlaub J., DeWitt J., et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005, 293:2003-2011.
135. Zink M.C., Laast V.A., Helke K.L., et al. From mice to macaques - animal models of HIV nervous system disease. Curr HIV Res 2006, 4:293-305.